These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 18394010)

  • 1. Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor.
    Bhatt RS; Landis DM; Zimmer M; Torregrossa J; Chen S; Sukhatme VP; Iliopoulos O; Balk S; Bubley GJ
    BJU Int; 2008 Aug; 102(3):358-63. PubMed ID: 18394010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reciprocal regulation of hypoxia-inducible factor 2α and GLI1 expression associated with the radioresistance of renal cell carcinoma.
    Zhou J; Wu K; Gao D; Zhu G; Wu D; Wang X; Chen Y; Du Y; Song W; Ma Z; Authement C; Saha D; Hsieh JT; He D
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):942-51. PubMed ID: 25585786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe.
    Rachamala HK; Madamsetty VS; Angom RS; Nakka NM; Dutta SK; Wang E; Mukhopadhyay D; Pal K
    J Exp Clin Cancer Res; 2024 Jun; 43(1):159. PubMed ID: 38840237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.
    Holland WS; Tepper CG; Pietri JE; Chinn DC; Gandara DR; Mack PC; Lara PN
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):185-94. PubMed ID: 21644050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.
    Elorza A; Soro-Arnáiz I; Meléndez-Rodríguez F; Rodríguez-Vaello V; Marsboom G; de Cárcer G; Acosta-Iborra B; Albacete-Albacete L; Ordóñez A; Serrano-Oviedo L; Giménez-Bachs JM; Vara-Vega A; Salinas A; Sánchez-Prieto R; Martín del Río R; Sánchez-Madrid F; Malumbres M; Landázuri MO; Aragonés J
    Mol Cell; 2012 Dec; 48(5):681-91. PubMed ID: 23103253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
    Liu MY; Poellinger L; Walker CL
    Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
    Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
    Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.
    Yoshino H; Nohata N; Miyamoto K; Yonemori M; Sakaguchi T; Sugita S; Itesako T; Kofuji S; Nakagawa M; Dahiya R; Enokida H
    Cancer Res; 2017 Nov; 77(22):6321-6329. PubMed ID: 28951458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
    Wysocki PJ
    Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
    Xiong Z; Zang Y; Zhong S; Zou L; Wu Y; Liu S; Fang Z; Shen Z; Ding Q; Chen S
    Oncotarget; 2017 May; 8(18):30151-30161. PubMed ID: 28404914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells.
    Mahajan S; Dammai V; Hsu T; Kraft AS
    Carcinogenesis; 2008 Sep; 29(9):1734-41. PubMed ID: 18544564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus resistance in clear cell renal cell carcinoma: miRNA-101 and HIF-2α as molecular triggers?
    Nogueira I; Dias F; Morais M; Teixeira AL; Medeiros R
    Future Oncol; 2019 Jul; 15(20):2361-2370. PubMed ID: 31267758
    [No Abstract]   [Full Text] [Related]  

  • 13. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma.
    Zheng B; Mao JH; Qian L; Zhu H; Gu DH; Pan XD; Yi F; Ji DM
    Cancer Lett; 2015 Feb; 357(2):468-75. PubMed ID: 25444920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
    Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
    Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Norcantharidin counteracts acquired everolimus resistance in renal cell carcinoma by dual inhibition of mammalian target of rapamycin complex 1 and complex 2 pathways in Vitro.
    Chen X; Cai X; Zheng D; Huang X; Chen Y; Deng T; Mo L; Li H; Li J; Chen S
    Anticancer Drugs; 2022 Jan; 33(1):e94-e102. PubMed ID: 34261913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIF2α is involved in the expansion of CXCR4-positive cancer stem-like cells in renal cell carcinoma.
    Micucci C; Matacchione G; Valli D; Orciari S; Catalano A
    Br J Cancer; 2015 Oct; 113(8):1178-85. PubMed ID: 26439684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
    Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
    Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia inducible factor (HIf1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy.
    Koukourakis MI; Giatromanolaki A; Danielidis V; Sivridis E
    Int J Radiat Biol; 2008 Jan; 84(1):47-52. PubMed ID: 17852557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer.
    Szendrői A; Szász AM; Kardos M; Tőkés AM; Idan R; Szűcs M; Kulka J; Nyirády P; Szendrői M; Szállási Z; Győrffy B; Tímár J
    Oncotarget; 2016 Jul; 7(27):42086-42098. PubMed ID: 27244898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.